{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T19:50:04Z","timestamp":1792180204270,"version":"4.4.0"},"reference-count":15,"publisher":"Pharmaceutical Society of Japan","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological & Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2019,9,1]]},"DOI":"10.1248\/bpb.b19-00168","type":"journal-article","created":{"date-parts":[[2019,8,31]],"date-time":"2019-08-31T22:03:46Z","timestamp":1567289026000},"page":"1596-1599","source":"Crossref","is-referenced-by-count":7,"title":["Measurement of Serum Tenascin-X in Joint Hypermobility Syndrome Patients"],"prefix":"10.1248","volume":"42","author":[{"given":"Kazuo","family":"Yamada","sequence":"first","affiliation":[{"name":"Department of Biosignaling and Radioisotope Experiment, Interdiscipnary Center for Science Research, Organization for Research and Academic Information, Shimane University"},{"name":"Department of Legal Medicine, Faculty of Medicine, Shimane University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Division of Clinical Genetics, Nippon Medical School Hospital"},{"name":"Division of Clinical Genetics, Kanazawa University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruo","family":"Takeshita","sequence":"additional","affiliation":[{"name":"Department of Legal Medicine, Faculty of Medicine, Shimane University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Fujita","sequence":"additional","affiliation":[{"name":"Department of Human Genetics, Yokohama City University Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriko","family":"Miyake","sequence":"additional","affiliation":[{"name":"Department of Human Genetics, Yokohama City University Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomichi","family":"Matsumoto","sequence":"additional","affiliation":[{"name":"Department of Human Genetics, Yokohama City University Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken-ichi","family":"Matsumoto","sequence":"additional","affiliation":[{"name":"Department of Biosignaling and Radioisotope Experiment, Interdiscipnary Center for Science Research, Organization for Research and Academic Information, Shimane University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"163","reference":[{"key":"1","unstructured":"1) Grahame R. Joint hypermobility and genetic collagen disorders: are they related? Arch. Dis. Child.<\/i>, 80<\/b>, 188\u2013191 (1999)."},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Malfait F, Hakim AJ, De Paepe A, Grahame R. The genetic basis of the joint hypermobility syndromes. Rheumatology<\/i>, 45<\/b>, 502\u2013507 (2006).","DOI":"10.1093\/rheumatology\/kei268"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Tinkle BT, Bird HA, Grahame R, Lavallee M, Levy HP, Sillence D. The lack of clinical distinction between the hypermobility type of Ehlers\u2013Danlos syndrome (a.k.a. hypermobility syndrome). Am. J. Med. Genet. A<\/i>, 149A<\/b>, 2368\u20132370 (2009).","DOI":"10.1002\/ajmg.a.33070"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Schalkwijk J, Zweers MC, Steijlen PM, Dean WB, Taylor G, van Vlijmen IM, van Haren B, Miller WL, Bristow J. A recessive form of the Ehlers\u2013Danlos syndrome caused by tenascin-X deficiency. N. Engl. J. Med.<\/i>, 345<\/b>, 1167\u20131175 (2001).","DOI":"10.1056\/NEJMoa002939"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Minamitani T, Ikuta T, Saito Y, Takebe G, Sato M, Sawa H, Nishimura T, Nakamura F, Takahashi K, Ariga H, Matsumoto K. Modulation of collagen fibrillogenesis by tenascin-X and type VI collagen. Exp. Cell Res.<\/i>, 298<\/b>, 305\u2013315 (2004).","DOI":"10.1016\/j.yexcr.2004.04.030"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Alcaraz LB, Exposito J-Y, Chuvin N, Pommier RM, Cluzel C, Martel S, Sentis S, Bartholin L, Lethias C, Valcourt U. Tenascin-X promotes epithelial-to-mesenchymal transition by activating latent TGF-\u03b2. J. Cell Biol.<\/i>, 205<\/b>, 409\u2013428 (2014).","DOI":"10.1083\/jcb.201308031"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Hashimoto K, Kajitani N, Miyamoto Y, Matsumoto K. Wound healing-related properties detected in an experimental model with a collagen gel contraction assay are affected in the absence of tenascin-X. Exp. Cell Res.<\/i>, 363<\/b>, 102\u2013113 (2018).","DOI":"10.1016\/j.yexcr.2017.12.025"},{"key":"8","unstructured":"8) Beighton P, De Paepe A, Steinmann B, Tsipouras P, Wenstrup RJ. Ehlers\u2013Danlos syndromes: revised nosology, Villefranche, 1997. Ehlers\u2013Danlos National Foundation (U.S.A.) and Ehlers\u2013Danlos Support Group (U.K.). Am. J. Med. Genet.<\/i>, 77<\/b>, 31\u201337 (1998)."},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Zweers MC, Bristow J, Steijlen PM, Dean WB, Hamel BC, Otero M, Kucharekova M, Boezeman JB, Schalkwijk J. Haploinsufficiency of TNXB is associated with hypermobility type of Ehlers\u2013Danlos syndrome. Am. J. Hum. Genet.<\/i>, 73<\/b>, 214\u2013217 (2003).","DOI":"10.1086\/376564"},{"key":"10","unstructured":"10) Malfait F, Francomano C, Byers P, et al.<\/i> The 2017 international classification of the Ehlers\u2013Danlos syndromes. Am. J. Med. Genet. C. Semin. Med. Genet.<\/i>, 175<\/b>, 8\u201326 (2017)."},{"key":"11","unstructured":"11) Grahame R, Bird HA, Child A. The revised (Brighton 1998) criteria for the diagnosis of benign joint hypermobility syndrome (BJHS). J. Rheumatol.<\/i>, 27<\/b>, 1777\u20131779 (2000)."},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Yamada K, Watanabe A, Takeshita H, Matsumoto K. A method for quantification of serum tenascin-X by nano-LC\/MS\/MS. Clin. Chim. Acta<\/i>, 459<\/b>, 94\u2013100 (2016).","DOI":"10.1016\/j.cca.2016.05.022"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Watanabe A, Satoh K, Maniwa T, Matsumoto K. Proteomic analysis for the identification of serum diagnostic markers for joint hypermobility syndrome. Int. J. Mol. Med.<\/i>, 37<\/b>, 461\u2013467 (2016).","DOI":"10.3892\/ijmm.2015.2437"},{"key":"14","unstructured":"14) Hamanaka K, Miyatake S, Zerem A, Lev D, Blumkin L, Yokochi K, Fujita A, Imagawa E, Iwama K, Nakashima M, Mitsuhashi S, Mizuguchi T, Takata A, Miyake N, Saitsu H, van der Knaap MS, Lerman-Sagie T, Matsumoto N. Expanding the phenotype of IBA57 mutations: related leukodystrophy can remain asymptomatic. J. Hum. Genet.<\/i>, 63<\/b>, 1223\u20131229 (2018)."},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Chiarelli N, Carini G, Zoppi N, Dordoni C, Ritelli M, Venturini M, Castori M, Colombi M. Transcriptome-wide expression profiling in skin fibroblasts of patients with joint hypermobility syndrome\/Ehlers\u2013Danlos syndrome hypermobility type. PLOS ONE<\/i>, 11<\/b>, e0161347 (2016).","DOI":"10.1371\/journal.pone.0161347"}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/42\/9\/42_b19-00168\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,7]],"date-time":"2019-09-07T03:20:51Z","timestamp":1567826451000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/42\/9\/42_b19-00168\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,1]]},"references-count":15,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b19-00168","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,1]]}}}